Real-world study of PD-L1 testing patterns and treatment distribution in patients with metastatic non-small-cell lung cancer in Israel

Sarah Sharman Moser*, Lior Apter, Ashwini Arunachalam, Thomas Burke, Varda Shalev, Gabriel Chodick, Nava Siegelmann-Danieli

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: We describe PD-L1 testing patterns and first-line treatment for patients with metastatic non-small-cell lung cancer in a 2.3 million-member state-mandated health service in Israel. Materials & methods: Newly diagnosed stage IV non-small-cell lung cancer patients initiating systemic anticancer treatment from 1 January 2017 until 31 December 2018 were identified from the national cancer registry and Maccabi Healthcare Service database and followed until 30 June 2019. Results: The cohort consisted of 410 patients; 58% males, median age 68 years, 70% current/former smokers, 81% adenocarcinoma, 14% had brain metastases, and Eastern Cooperative Oncology Group performance status was 46/17/37% for 0-1/2-4/unknown, respectively. A total of 80% tested for PD-L1 expression, of which 47% had tumor proportion score (TPS) ≥ 50%. A total of 95% with TPS ≥ 50% and no known tumor aberrations (including EGFR mutations, and translocations in ALK and ROS1) received first-line PD-1/PD-L1-inhibitor monotherapy, and 80% of untested/TPS < 50% received platinum doublets. Conclusion: Fast uptake of testing was observed, and treatment patterns showed high adherence to guidelines.

Original languageEnglish
Pages (from-to)851-861
Number of pages11
JournalImmunotherapy
Volume13
Issue number10
DOIs
StatePublished - Jul 2021

Keywords

  • PD-L1 testing
  • non-small-cell lung cancer
  • treatment patterns

Fingerprint

Dive into the research topics of 'Real-world study of PD-L1 testing patterns and treatment distribution in patients with metastatic non-small-cell lung cancer in Israel'. Together they form a unique fingerprint.

Cite this